Funding for this research was provided by:
Received: 11 October 2018
Accepted: 12 March 2019
First Online: 3 April 2019
Ethics approval and consent to participate
: The clinical trial protocol was approved by an Institutional Review Board (Chesapeake Research Review; Pro00007797), and each patient provided written informed consent before participating in the study.
: Not applicable.
: DAR and IW are employees of Evidera. Evidera received funding from Amgen Inc. for the conduct of this study and for the preparation of the manuscript.DAR has research grants with and receives consulting fees from Amgen Inc., Allergan, GlaxoSmithKline, Abbvie, and Takeda.GG and HZ are employees and shareholders of Amgen Inc.MM is currently an employee of the PRO Consortium (formerly was employed by Evidera).
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.